Register Login

Abiopharma

  • Home
  • About
  • Newsroom
    • News
    • Company List
  • Events
  • Automated Tools
  • Contact

News list

9 Meters Biopharma, Inc. (NMTRQ)

  • Business News
  • Dec. 13, 2025, 20:28 UTC
  • 3
  • 1 comments

Best Dash Cams (2026)

Market reaction Comment Full text

9 Meters Biopharma, Inc. (NMTRQ)

  • Business News
  • Dec. 13, 2025, 20:25 UTC
  • 3
  • 1 comments

Best Smart Air Purifiers (2026)

Market reaction Comment Full text

Scholar Rock Holding Corp (SRRK)

  • Business News
  • Dec. 13, 2025, 15:57 UTC
  • 3
  • 1 comments

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Market reaction Comment Full text

Integer Holdings Corp (ITGR)

  • Business News
  • Dec. 13, 2025, 03:14 UTC
  • 9
  • 1 comments

Integer Holdings Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuits Against Integer Holdings Corporation - ITGR

Market reaction Comment Full text

MoonLake Immunotherapeutics (MLTX)

  • Business News
  • Dec. 13, 2025, 01:51 UTC
  • 4
  • 1 comments

Deadline Soon: MoonLake Immunotherapeutics (MLTX) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

Market reaction Comment Full text

Integer Holdings Corp (ITGR)

  • Business News
  • Dec. 13, 2025, 01:46 UTC
  • 3
  • 1 comments

ITGR Stockholder Alert: Robbins LLP Reminds Investors of the Integer Holdings Corporation Securities Class Action

Market reaction Comment Full text

Johnson & Johnson (JNJ)

  • Business News
  • Dec. 13, 2025, 01:27 UTC
  • 3
  • 1 comments

Johnson & Johnson - U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*

Market reaction Comment Full text

Johnson & Johnson (JNJ)

  • Business News
  • Dec. 13, 2025, 01:25 UTC
  • 2
  • 1 comments

U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*

Market reaction Comment Full text

NervGen Pharma Corp. (NGENF)

  • Business News
  • Dec. 13, 2025, 01:00 UTC
  • 2
  • 1 comments

NervGen Pharma Announces Proposed Amendment to Warrants

Market reaction Comment Full text

Milestone Pharmaceuticals Inc (MIST)

  • Business News
  • Dec. 13, 2025, 01:00 UTC
  • 2
  • 1 comments

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

Market reaction Comment Full text
  • Previous
  • 12
  • 13
  • 14
  • 15
  • 16
  • Next

Search

News categories

  • Technical Exchange News(10571)
  • Event(1927)
  • SEC News(183549)
  • FDA Approval(9807)
  • Company Report(721)
  • Business News(121675)
Market reaction

© Copyright Abiopharma. All Rights Reserved
Designed by Alexey Vershinin